Ko‘krak bezi raki erta tashxis va zamonaviy davolash yondashuvlari
Keywords:
ko‘krak bezi raki, erta tashxis, mammografiya, biopsiya, biomarkerlar, immunoterapiya, nishonli terapiyaAbstract
Ko‘krak bezi rakida erta diagnostika va o‘smaning biologik xususiyatlariga mos davolash kasallik oqibatlarini yaxshilashning asosiy yo‘nalishlaridir. Maqsad diagnostika, skrining va davolash bo‘yicha zamonaviy dalillarni tahlil qilishdir.WHO, NCI, USPSTF va FDAning rasmiy materiallari hamda PubMedda indekslangan klinik sinovlar annotatsiyalari narrativ usulda tahlil qilindi. Ma’lumotlar manbasi, bemor guruhi, taqqoslangan davo, kuzatuv muddati va natija turi bo‘yicha ajratildi.Tahlilga 12 ta manba, jumladan 9 ta rasmiy material va 3 ta randomizatsiyalangan klinik sinov nashri kiritildi. Diagnostik sintez biopsiya, kasallik bosqichi va ER, PR hamda HER2 holatini baholashga asoslandi. KEYNOTE-522 sinovida pembrolizumab asosidagi davolash va nazorat guruhlari o‘rtasidagi 60 oylik umumiy yashovchanlik farqi 4,9 foiz punktini tashkil etdi.References
1. World Health Organization. Breast cancer. Yangilangan sana: 3 July 2026. Manba havolasi
2. World Health Organization. Global breast cancer initiative implementation framework: assessing, strengthening and scaling up of services for the early detection and management of breast cancer. Geneva: WHO; 2023. ISBN 978-92-4-006598-7. Manba havolasi
3. National Cancer Institute. Breast Cancer Causes and Risk Factors. Manba havolasi
4. National Cancer Institute. How Breast Cancer Is Diagnosed. Manba havolasi
5. National Cancer Institute. Tests for Breast Cancer Biomarkers. Manba havolasi
6. US Preventive Services Task Force. Breast Cancer: Screening. Final recommendation statement. 30 April 2024. Manba havolasi
7. PDQ Adult Treatment Editorial Board. Breast Cancer Treatment (PDQ®)–Health Professional Version. National Cancer Institute. Manba havolasi
8. National Cancer Institute. Breast Cancer Treatment. Manba havolasi
9. Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med. 2024;390(12):1080–1091. doi:10.1056/NEJMoa2305488. Manba havolasi
10. Schmid P, Cortes J, Dent R, et al. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med. 2024;391(21):1981–1991. doi:10.1056/NEJMoa2409932. Manba havolasi
11. Geyer CE Jr, Untch M, Huang CS, et al. Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer. N Engl J Med. 2025;392(3):249–257. doi:10.1056/NEJMoa2406070. Manba havolasi
12. US Food and Drug Administration. FDA approves two separate indications for fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer. 15 May 2026. Manba havolasi
Published
Issue
Section
License
Ushbu jurnalda chop etilgan maqolalar Creative Commons Attribution 4.0 Xalqaro Litsenziyasi (CC BY 4.0) ostida litsenziyalangan. Bu asarni nusxalash, tarqatish va moslashtirish imkonini beradi, agar asl muallif va manba to'g'ri ko'rsatilsa.
